Gastric Cancer Third Line
1 clinical trials · Condition
◉ Watch Gastric Cancer Third Line
| Record | Firm | Date |
|---|---|---|
| Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) (NCT02625623) | EMD Serono Research & Development Institute, Inc. | 2015-12-28 |
Track Gastric Cancer Third Line automatically
Every clearance here is in the API, with alerts when new ones post.